Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 10/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 17/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
| ▸ | LTK | P29376 | 1/20 | 0.47 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060820 | 0.91 | S1PR1 (0.52) | S1PR5S1PR1 | |
| SCHEMBL10060821 | 0.87 | S1PR1 (0.51) | S1PR5S1PR1S1PR3 | |
| SCHEMBL9107584 | 0.85 | S1PR1 (0.49) | S1PR5S1PR1LTKTAOK1 | |
| SCHEMBL10061463 | 0.84 | S1PR1 (0.51) | S1PR5S1PR1S1PR3 | |
| SCHEMBL10060690 | 0.81 | S1PR1 (0.49) | S1PR5S1PR1 | |
| SCHEMBL16695243 | 0.80 | S1PR5 (0.82) | S1PR5S1PR1S1PR3LTKTAOK1 | |
| SCHEMBL16504302 | 0.78 | S1PR1 (0.51) | S1PR5S1PR1S1PR3 | |
| SCHEMBL3036853 | 0.78 | S1PR5 (0.74) | S1PR5S1PR1S1PR3 | |
| SCHEMBL10061464 | 0.78 | S1PR5 (0.69) | S1PR5S1PR1S1PR3 | |
| SCHEMBL16504354 | 0.77 | S1PR1 (0.50) | S1PR5S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142662-A1 | NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142662-A1 | NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR2, S1PR5 | S1PR5 3/4885S1PR1 1/4885S1PR3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.